CiVi Biopharma
Chuck joined CiVi Biopharma in August 2017 as chief development officer and leads the clinical development programs at CiVi Biopharma. Chuck has more than 32 years of clinical drug development experience at Merck Research Laboratories, Consolidated Serum Laboratories (CSL), Ltd and Pfizer Global R&D, where he held positions of increasing responsibility in clinical, regulatory and therapeutic area strategy and operations. Chuck’s primary therapeutic focus has been in cardiovascular disease and dyslipidemia.
This person is not in any offices
CiVi Biopharma
CiVi Biopharma Inc. is a US-based, privately-held biopharmaceutical company, founded in 2016. The Company's research and development activities are focused on creating novel therapies for cardiovascular, metabolic and related diseases. CiVi’s innovative pipeline includes CiVi007, a long-acting PCSK9 third-generation Locked Nucleic Acid antisense molecule being developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, the Company currently has other clinical stage development program activity aimed at treating severe liver diseases.